Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.

<h4>Objective</h4>Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sergio Raposeiras-Roubín, Bruno K Rodiño-Janeiro, Beatriz Paradela-Dobarro, Lilian Grigorian-Shamagian, José M García-Acuña, Pablo Aguiar-Souto, Michel Jacquet-Hervet, María V Reino-Maceiras, José R González-Juanatey, Ezequiel Álvarez
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e9d1cb361344473b8e3e8cf84712cd36
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9d1cb361344473b8e3e8cf84712cd36
record_format	dspace
spelling	oai:doaj.org-article:e9d1cb361344473b8e3e8cf84712cd362021-11-18T08:55:21ZFluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.1932-620310.1371/journal.pone.0074302https://doaj.org/article/e9d1cb361344473b8e3e8cf84712cd362013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24058542/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period.<h4>Methods</h4>A prospective clinical study was performed in patients with debut's ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273-519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score.<h4>Results</h4>The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis.<h4>Conclusions</h4>We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events.Sergio Raposeiras-RoubínBruno K Rodiño-JaneiroBeatriz Paradela-DobarroLilian Grigorian-ShamagianJosé M García-AcuñaPablo Aguiar-SoutoMichel Jacquet-HervetMaría V Reino-MaceirasJosé R González-JuanateyEzequiel ÁlvarezPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 9, p e74302 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sergio Raposeiras-Roubín Bruno K Rodiño-Janeiro Beatriz Paradela-Dobarro Lilian Grigorian-Shamagian José M García-Acuña Pablo Aguiar-Souto Michel Jacquet-Hervet María V Reino-Maceiras José R González-Juanatey Ezequiel Álvarez Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
description	<h4>Objective</h4>Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period.<h4>Methods</h4>A prospective clinical study was performed in patients with debut's ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273-519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score.<h4>Results</h4>The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis.<h4>Conclusions</h4>We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events.
format	article
author	Sergio Raposeiras-Roubín Bruno K Rodiño-Janeiro Beatriz Paradela-Dobarro Lilian Grigorian-Shamagian José M García-Acuña Pablo Aguiar-Souto Michel Jacquet-Hervet María V Reino-Maceiras José R González-Juanatey Ezequiel Álvarez
author_facet	Sergio Raposeiras-Roubín Bruno K Rodiño-Janeiro Beatriz Paradela-Dobarro Lilian Grigorian-Shamagian José M García-Acuña Pablo Aguiar-Souto Michel Jacquet-Hervet María V Reino-Maceiras José R González-Juanatey Ezequiel Álvarez
author_sort	Sergio Raposeiras-Roubín
title	Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
title_short	Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
title_full	Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
title_fullStr	Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
title_full_unstemmed	Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
title_sort	fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/e9d1cb361344473b8e3e8cf84712cd36
work_keys_str_mv	AT sergioraposeirasroubin fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT brunokrodinojaneiro fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT beatrizparadeladobarro fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT liliangrigorianshamagian fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT josemgarciaacuna fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT pabloaguiarsouto fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT micheljacquethervet fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT mariavreinomaceiras fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT josergonzalezjuanatey fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT ezequielalvarez fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
_version_	1718421174745038848

Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.

Ejemplares similares